ANI Pharmaceuticals Inc (ANIP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

210 MAIN STREET WEST BAUDETTE, MN 56623

BioSante Pharmaceuticals is a pharmaceutical company focused on developing products for female sexual health and oncology. Co.'s products for female sexual health, menopause, contraception and male hypogonadi® include its gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen. Co.'s products, either approved or in human clinical development, include LibiGel, a once daily transdermal testosterone gel; a male testosterone gel; GVAX cancer vaccines; the Pill-Plus, a once daily use of various combinations of estrogens, progestogens and androgens; as well as Elestrin, a once daily transdermal estradiol (estrogen) gel.

Data as of 2020-07-04
Market Cap381.206 Million Shares Outstanding12.341 Million Avg 30-day Volume164.358 Thousand
P/E Ratio Dividend Yield EPS-0.13
Price/Sales2.555 Price cash flow ratio11.3 Price free cash flow ratio-11.7
Book Value16.3 Price to Tangible Book-21.15 Alpha-0.02
Short Interest Ratio % Short Interest to Float R-squared0.231941
BETA1.51502 52-week High/Low86.96 / 28.28 Stddev0.133963
View SEC Filings from ANIP instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 142 40 (2.62%)
Aggregate 13F shares on 03/31/2020: 7.942 Million 3.322 Million
Aggregate 13F shares on 12/31/2019: 8.074 Million 3.095 Million
Percent change: -1.63% 7.36%
Funds creating new positions: 14 4
Funds Adding to an existing position: 48 15
Funds closing out their position: 38 11
Funds reducing their position: 55 21
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ANIP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANIP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SULLIVAN LOUIS W

  • Director
9,420 2020-06-26 0

HOLUBOW FRED

  • Director
0 2020-06-05 0

DONENBERG PHILLIP B.

  • Director
0 2020-06-04 0

SHERWIN STEPHEN A

  • Director
16,328 2020-06-03 0

WALSH PATRICK D INTERIM PRESIDENT AND CEO

  • Officer
  • Director
20,096 2020-05-11 2

MARKEN JAMES G. SVP OPS & PROD DEV

  • Officer
85,297 2020-04-10 2

SCHREPFER ROBERT W SVP - NEW BUS DEV & SPEC SALES

  • Officer
93,043 2020-04-10 3

BROWN ROBERT E. JR

  • Director
29,680 2020-04-10 1

CAREY STEPHEN P. VICE PRESIDENT AND CFO

  • Officer
63,145 2020-04-10 3

NASH DAVID

  • Director
12,355 2020-04-10 1

HAUGHEY THOMAS

  • Director
18,410 2020-04-10 2

PRZYBYL ARTHUR PRESIDENT AND CEO

  • Officer
  • Director
190,309 2020-04-06 2

MERIDIAN VENTURE PARTNERS II LP

MERIDIAN VENTURE PARTNERS II GP, L.P.

MERIDIAN VENTURE PARTNERS II, CO.

BROWN ROBERT E. JR

  • Director
  • 10% Owner
2,281,283 2019-08-19 4

PENN THOMAS A.

  • Director
14,301 2019-03-28 0

MARSHBANKS TRACY

  • Director
349,934 2018-05-14 0

RAYNOR DANIEL

  • Director
289,003 2018-03-15 0

POTTS JOHN T JR

  • Director
159,253 2017-06-09 0

ARNOLD CHARLOTTE C. VICE PRESIDENT AND CFO

  • Officer
54,298 2016-04-07 0

LANKAU PETER A

  • Director
2,500 2016-04-07 0

MANGANO ROSS J

  • Director
26,914 2014-09-15 0

SIMES STEPHEN M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2014-07-24 0

JAMNICK ROBERT J. VP, QUALITY & PRODUCT DEVELOP.

  • Officer
48,118 2014-05-22 0

BROWN ROBERT E. JR

PENN THOMAS A.

  • Director
  • 10% Owner
16,918,469 2013-06-19 0

MERIDIAN VENTURE PARTNERS II LP

MERIDIAN VENTURE PARTNERS II GP, L.P.

MERIDIAN VENTURE PARTNERS II, CO.

  • 10% Owner
16,918,469 2013-06-19 0

ROSENOW EDWARD C III

  • Director
20,540 2012-03-30 0

SNABES MICHAEL C SR. VP OF MEDICAL AFFAIRS

  • Officer
0 2012-01-25 0

KJAER PETER

  • Director
34,425 2010-03-31 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments